Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: EPO Clear all
Terminated Phase 3 Interventional Accepts healthy volunteers

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

NCT00254436
View directory record Official record
Conditions
Gastrointestinal Cancer, Rectal Cancer
Interventions
Procrit (epoetin alfa)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 4, 2026, 7:41 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

NCT00454246
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

NCT00416624
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, epoetin alfa, fatigue assessment and management, quality-of-life assessment
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 4, 2026, 7:41 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

NCT01737879
View directory record Official record
Conditions
Anemia
Interventions
Peginesatide, Epoetin alfa
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Tempe, Arizona • Azusa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

NCT04484857
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Anchorage, Alaska • Pine Bluff, Arkansas • Cerritos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 2Phase 3 Interventional Results available

2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

NCT00223977
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Sodium Ferric Gluconate Complex, Oral Iron
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2013 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01628107
View directory record Official record
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
108
States / cities
Azusa, California • Bellflower, California • Commerce, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 3 Interventional

Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer

NCT00004917
View directory record Official record
Conditions
Anemia, Head and Neck Cancer
Interventions
epoetin alfa, cisplatin, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
240
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

High-dose Erythropoietin for Asphyxia and Encephalopathy

NCT02811263
View directory record Official record
Conditions
Neonatal Encephalopathy, Birth Asphyxia
Interventions
Normal saline placebo, Erythropoietin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 24 Hours
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
23
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

NCT00058422
View directory record Official record
Conditions
Lymphoma
Interventions
darbepoetin alfa, filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan
Biological · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

NCT04313153
View directory record Official record
Conditions
Anemia
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Chula Vista, California • Granada Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 4, 2026, 7:41 AM EDT
Terminated Phase 3 Interventional Results available

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

NCT00422513
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, Epoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
44
States / cities
Birmingham, Alabama • Rainbow City, Alabama • Hot Springs, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2011 · Synced Sep 4, 2026, 7:41 AM EDT
Not listed Phase 2 Interventional

Treatment of Chronic Anemia With Epoetin Alfa in Elderly

NCT00337441
View directory record Official record
Conditions
Anemia
Interventions
Epoetin Alfa (drug)
Drug
Lead sponsor
Research and Education Foundation of Michael Reese Hospital
Other
Eligibility
65 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2006 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

NCT00077610
View directory record Official record
Conditions
Anemia
Interventions
Epoetin alfa or beta, RO0503821 (1x/2 Weeks), RO0503821 (1x/4 Weeks)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
60
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 2 Interventional

Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue

NCT00004914
View directory record Official record
Conditions
Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa, physical therapy
Biological · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction

NCT00367991
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Recombinant human erythropoietin alfa (drug), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 4, 2026, 7:41 AM EDT
Withdrawn No phase listed Observational

Effect of Vitamin D Supplementation on Erythropoietin Dosage in Hemodialysis Patients Who Have Vitamin D Deficiency

NCT00915317
View directory record Official record
Conditions
Vitamin D Deficiency, Anemia
Interventions
Not listed
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

NCT00049348
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
epoetin alfa, filgrastim, cisplatin, fluorouracil, gemcitabine hydrochloride, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
137
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boca Raton, Florida + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 4, 2026, 7:41 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Pharmacological Countermeasures for High Altitude

NCT05300477
View directory record Official record
Conditions
Hypobaric Hypoxia
Interventions
Acetazolamide, Erythropoietin
Drug
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

NCT03169881
View directory record Official record
Conditions
Neurocognitive, Neuroprotective, Neonatal, Neurodevelopmental Impairment
Interventions
Darbepoetin, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
1 Hour to 24 Hours
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 4, 2026, 7:41 AM EDT
Terminated Phase 2 Interventional Results available

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

NCT00372489
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Pine Bluff, Arkansas • Mountain View, California • Lauderdale Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

NCT02412449
View directory record Official record
Conditions
Healthy
Interventions
AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 4, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

NCT00442702
View directory record Official record
Conditions
Anemia
Interventions
Mircera, Darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
11
States / cities
Granada Hills, California • Lauderdale Lakes, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2011 · Synced Sep 4, 2026, 7:41 AM EDT
Terminated Phase 2 Interventional Results available

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

NCT00496379
View directory record Official record
Conditions
Breast Cancer, CNS Disease
Interventions
ZK219477
Drug
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 4, 2026, 7:41 AM EDT